Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Вакцинопрофилактика против пневмококковой инфекции и сердечно-сосудистые заболевания - Журнал Терапевтический архив №9 Вопросы кардиологии 2025
Вакцинопрофилактика против пневмококковой инфекции и сердечно-сосудистые заболевания
Щелкова Г.В., Яровой С.Ю., Диневич Е.О., Чазова И.Е. Вакцинопрофилактика пневмококковой инфекции и сердечно-сосудистые заболевания. Терапевтический архив. 2025;97(9):793–799. DOI: 10.26442/00403660.2025.09.203423
© ООО «КОНСИЛИУМ МЕДИКУМ», 2025 г.
© ООО «КОНСИЛИУМ МЕДИКУМ», 2025 г.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Сердечно-легочная коморбидность – серьезная угроза для здоровья в любом возрасте. Внебольничная пневмония, вызванная Streptococcus pneumoniae, имеет доказанный негативный эффект в плане частоты развития новых и декомпенсации известных сердечно-сосудистых патологий, таких как инфаркт миокарда, нарушение мозгового кровообращения, сердечная недостаточность. Дополнительными стимулами широкого применения вакцинопрофилактики пневмококковой инфекции (ПКИ) являются хорошая доступность вакцины и простая схема иммунизации. Однако действующие рекомендации имеют значительные расхождения мнений относительно целевых групп для вакцинации как между собой, так и с существующей доказательной базой. Низкая распространенность вакцинопрофилактики от пневмококка не позволяет в полной мере использовать даже хорошо известные преимущества этого метода в снижении сердечно-сосудистого риска. В обзоре обсуждаются возможные механизмы воздействия ПКИ на организм человека, кардиопротективные эффекты вакцинации, современные работы о возможностях вакцинации у лиц с сердечно-сосудистыми заболеваниями, рассматривается влияние вакцинации на частоту сердечно-сосудистых событий и уровень смертности. Обозначается место профилактики ПКИ в действующих клинических рекомендациях, исследуется ее влияние на прогноз пациентов. Утверждается необходимость проведения дальнейших исследований с целью получения достаточных данных о протективном эффекте вакцинации для конкретных сердечно-сосудистых заболеваний и целевых групп пациентов.
Ключевые слова: сердечно-сосудистые заболевания, внебольничная пневмония, пневмококковая инфекция, вакцина, вакцинопрофилактика, смертность
Keywords: cardiovascular diseases, community-acquired pneumonia, pneumococcal infection, vaccine, vaccine prophylaxis, mortality rate
Ключевые слова: сердечно-сосудистые заболевания, внебольничная пневмония, пневмококковая инфекция, вакцина, вакцинопрофилактика, смертность
________________________________________________
Keywords: cardiovascular diseases, community-acquired pneumonia, pneumococcal infection, vaccine, vaccine prophylaxis, mortality rate
Полный текст
Список литературы
1. Здравоохранение в России. 2023. Статистический сборник. М. 2023 [Zdravookhranenie v Rossii. 2023. Statisticheskii sbornik. Moscow. 2023 (in Russian)].
2. Авдеев С.Н., Дехнич А.В., Зайцев А.А., и др. Внебольничная пневмония у взрослых. Клинические рекомендации. 2024. Режим доступа: https://spulmo.ru/upload/KR-vnebolnichnaya-pnevmoniya-u-vzros lyh-2024.pdf. Ссылка активна на 18.04.2025 [Avdeev SN, Dekhnich AV, Zaitsev AA, et al. Vnebol'nichnaia pnevmoniia u vzroslykh. Klinicheskie rekomendatsii. 2024. Available at: https://spulmo.ru/upload/KR-vnebolnichnaya-pnevmoniya-u-vzroslyh-2024.pdf. Accessed: 18.04.2025 (in Russian)].
3. Подзолков В.И., Драгомирецкая Н.А., Медведев И.Д., и др. Уровни кардиоспецифичных биомаркеров и показатели трехлетней выживаемости у госпитализированных больных с хронической сердечной недостаточностью и внебольничной пневмонией. Российский кардиологический журнал. 2024;29(6):5875 [Podzolkov VI, Dragomiretskaya NA, Medvedev ID, et al. Levels of cardiac biomarkers and three-year survival rate in hospitalized patients with heart failure and community-acquired pneumonia. Russian Journal of Cardiology. 2024;29(6):5875 (in Russian)]. DOI:10.15829/1560-4071-2024-5875
4. Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation. 2012;125(6):773-81. DOI:10.1161/CIRCULATIONAHA.111.040766
5. Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med. 2008;168(8):847-54. DOI:10.1001/archinte.168.8.847
6. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007;45(2):158-65. DOI:10.1086/518849
7. Chen LF, Chen HP, Huang YS, et al. Pneumococcal pneumonia and the risk of stroke: a population-based follow-up study. PLoS One. 2012;7(12):e51452. DOI:10.1371/journal.pone.0051452
8. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-25. DOI:10.1056/NEJMoa1408544
9. Арутюнов А.Г., Драгунов Д.О., Арутюнов Г.П., и др. Первое открытое исследование синдрома острой декомпенсации сердечной недостаточности и сопутствующих заболеваний в Российской Федерации. Независимый регистр ОРАКУЛ-РФ. Кардиология. 2015;55(5):12-21 [Arutyunov AG, Dragunov DO, Arutyunov GP, et al. First Open Study of Syndrome of Acute Decompensation of Heart Failure and Concomitant Diseases in Russian Federation: Independent Registry ORAKUL. Kardiologiia. 2015;55(5):12-21 (in Russian)]. DOI:10.18565/cardio.2015.5.12-21
10. Брико Н.И., Коршунов В.А., Ломоносов К.С. Пневмококковая инфекция в Российской Федерации: состояние проблемы. Вестник Российской академии медицинских наук. 2021;76(1):28-42 [Briko NI, Korshunov VA, Lomonosov KS. Pneumococcal infection in Russia: state of the issue. Annals of the Russian Academy of Medical Sciences. 2021;76(1):28-42 (in Russian)]. DOI:10.15690/vramn1404
11. Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia (Nathan). 2020;12:11. DOI:10.1186/s41479-020-00074-3
12. Захаренков И.А., Рачина С.А., Дехнич Н.Н., и др. Этиология тяжелой внебольничной пневмонии у взрослых: результаты первого российского многоцентрового исследования. Терапевтический архив. 2020;92(1):36-42 [Zakharenkov IA, Rachina SA, Dekhnich NN, et al. Etiology of severe community-acquired pneumonia in adults: results of the first Russian multicenter study. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(1):36-42 (in Russian)]. DOI:10.26442/ 00403660.2020.01.000491
13. Brown AO, Mann B, Gao G, et al. Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog. 2014;10(9):e1004383. DOI:10.1371/journal.ppat.1004383
14. Gilley RP, González-Juarbe N, Shenoy AT, et al. Infiltrated Macrophages Die of Pneumolysin-Mediated Necroptosis following Pneumococcal Myocardial Invasion. Infect Immun. 2016;84(5):1457-69. DOI:10.1128/IAI.00007-16
15. Alhamdi Y, Neill DR, Abrams ST, et al. Circulating Pneumolysin Is a Potent Inducer of Cardiac Injury during Pneumococcal Infection. PLoS Pathog. 2015;11(5):e1004836. DOI:10.1371/journal.ppat.1004836
16. Reyes LF, Restrepo MI, Hinojosa CA, et al. Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling. Am J Respir Crit Care Med. 2017;196(5):609-20. DOI:10.1164/rccm.201701-0104OC
17. Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med. 2011;8(6):e1001048. DOI:10.1371/journal.pmed.1001048
18. Bazaz R, Francis S, Dockrell D. 215 Increased Atherosclerotic Plaque Macrophage Content following Streptococcus Pneumoniae Pneumonia. Heart. 2015;101(Suppl. 4):A117.2-A118. DOI:10.1136/heartjnl-2015-308066.215
19. Restrepo MI, Reyes LF, Anzueto A. Complication of Community-Acquired Pneumonia (Including Cardiac Complications). Semin Respir Crit Care Med. 2016;37(6):897-904. DOI:10.1055/s-0036-1593754
20. Nel JG, Durandt C, Mitchell TJ, et al. Pneumolysin Mediates Platelet Activation In Vitro. Lung. 2016;194(4):589-93. DOI:10.1007/s00408-016-9900-5
21. Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264-74. DOI:10.1001/jama.2014.18229
22. Mamcarz A, Wełnicki M, Drożdż J, et al. The role of pneumococcal vaccination in reducing cardiovascular risk in cardiac patients: Expert opinion of the Prevention Committee of the Polish Cardiac Society supported by the Polish Vaccinology Society. Kardiol Pol. 2023;81(10):1038-106. DOI:10.33963/v.kp.96718
23. Falkenhorst G, Remschmidt C, Harder T, et al. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis. PLoS One. 2017;12(1):e0169368. DOI:10.1371/journal.pone.0169368
24. Diao WQ, Shen N, Yu PX, et al. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials. Vaccine. 2016;34(13):1496-503. DOI:10.1016/j.vaccine.2016.02.023
25. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010;10(2):83-92. DOI:10.1016/S1473-3099(09)70331-7
26. Ciszewski A. Cardioprotective effect of influenza and pneumococcal vaccination in patients with cardiovascular diseases. Vaccine. 2018;36(2):202-10. DOI:10.1016/j.vaccine.2017.11.078
27. Hörkkö S, Bird DA, Miller E, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest. 1999;103(1):117-28. DOI:10.1172/JCI4533
28. Shaw PX, Hörkkö S, Chang MK, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest. 2000;105(12):1731-40. DOI:10.1172/JCI8472
29. Ren S, Hure A, Peel R, et al. Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE). Am Heart J. 2016;177:58-65. DOI:10.1016/j.ahj.2016.04.003
30. Драпкина О.М., Брико Н.И., Костинов М.П., и др. Иммунизация взрослых. Методические рекомендации. М.: ФГБУ «НМИЦ ТПМ» Минздрава России, 2020 [Drapkina OM, Briko NI, Kostinov MP, et al. Immunizatsiia vzroslykh. Metodicheskie rekomendatsii. Moscow: FGBU «NMITs TPM» Minzdrava Rossii, 2020 (in Russian)].
31. Коршунов В.А., Брико Н.И., Полибин Р.В., и др. Охват вакцинацией против пневмококковой инфекции взрослых групп риска в Российской Федерации. Эпидемиология и Вакцинопрофилактика. 2025;23(6):13-23 [Korshunov VA, Briko NI, Polibin RV, et al. Pneumococcal Vaccination Coverage Among Adults at Risk in the Russian Federation. Epidemiology and Vaccinal Prevention. 2025;23(6):13-23 (in Russian)]. DOI:10.31631/2073-3046-2024-23-6-13-23
32. Marra F, Zhang A, Gillman E, et al. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis. Int J Infect Dis. 2020;99:204-13. DOI:10.1016/j.ijid.2020.07.038
33. Jaiswal V, Ang SP, Lnu K, et al. Effect of Pneumococcal Vaccine on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. J Clin Med. 2022;11(13):3799. DOI:10.3390/jcm11133799
34. Bhatt AS, Liang L, DeVore AD, et al. Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart Failure. JACC Heart Fail. 2018;6(10):844-55. DOI:10.1016/j.jchf.2018.04.012
35. Papagiannis D, Kourek C, Briasoulis A, et al. Pneumococcal and Influenza Vaccination Coverage in Patients with Heart Failure: A Systematic Review. J Clin Med. 2024;13(11):3029. DOI:10.3390/jcm13113029
36. Рудакова А.В., Брико Н.И., Лобзин Ю.В., и др. Фармакоэкономическая эффективность вакцинации против пневмококковой инфекции пациентов с хронической сердечной недостаточностью. Кардиология. 2023;63(5):19-26 [Rudakova AV, Brico NI, Lobzin YV, et al. Cost-effectiveness of pneumococcal vaccination among patients with chronic heart failure. Kardiologiia. 2023;63(5):19-26 (in Russian)]. DOI:10.18087/cardio.2023.5.n2378
37. Игнатова Г.Л., Антонов В.Н. Анализ влияния вакцинации против пневмококковой инфекции на течение коморбидной патологии у пациентов с хронической обструктивной болезнью легких и хронической сердечной недостаточностью. Терапевтический архив. 2018;90(8):53-62 [Ignatova GL, Antonov VN. Analysis of the influence of vaccination against pneumococcal infection on the course of comorbid pathology in patients with chronic obstructive pulmonary disease and chronic heart failure. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(8):53-62 (in Russian)].
38. Vlachopoulos CV, Terentes-Printzios DG, Aznaouridis KA, et al. Association between pneumococcal vaccination and cardiovascular outcomes: a systematic review and meta-analysis of cohort studies. Eur J Prev Cardiol. 2015;22(9):1185-99. DOI:10.1177/2047487314549512
39. Antunes M, Duarte GS, Brito D, et al. Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. 2021;7(1):97-106. DOI:10.1093/ehjqcco/qcaa030
40. Авдеев С.Н., Барбараш О.Л., Валиева З.С., и др. Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(11):6161 [Avdeev SN, Barbarash OL, Valieva ZS, et al. 2024 Clinical practice guidelines for pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian Journal of Cardiology. 2024;29(11):6161 (in Russian)]. DOI:10.15829/1560-4071-2024-6161
41. Галявич А.С., Терещенко С.Н., Ускач Т.М., и др. Хроническая сердечная недостаточность. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(11):6162 [Galyavich AS, Tereshchenko SN, Uskach TM, et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):6162 (in Russian)]. DOI:10.15829/1560-4071-2024-6162
42. Арутюнов Г.П., Палеев Ф.Н., Моисеева О.М., и др. Миокардиты у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(11):4790 [Arutyunov GP, Paleev FN, Moiseeva OM, et al. 2020 Clinical practice guidelines for Myocarditis in adults. Russian Journal of Cardiology. 2021;26(11):4790 (in Russian)]. DOI:10.15829/1560-4071-2021-4790
43. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216-23. DOI:10.7326/0003-4819-107-2-216
44. Чазова И.Е., Мартынюк Т.В., Валиева З.С., и др. Евразийские рекомендации по диагностике и лечению хронической тромбоэмболической легочной гипертензии (2020). Евразийский Кардиологический Журнал. 2021;(1):6-43 [Chazova IE, Martynyuk TV, Valieva ZS, et al. Eurasian association of cardiology (eac) guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (2020). Eurasian Heart Journal. 2021;(1):6-43 (in Russian)]. DOI:10.38109/2225-1685-2021-1-6-43
45. Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J. 2023;44(39):3948-4042. DOI:10.1093/eurheartj/ehad193
46. Waghorn DJ, Mayon-White RT. A study of 42 episodes of overwhelming post-splenectomy infection: is current guidance for asplenic individuals being followed? J Infect. 1997;35(3):289-94. DOI:10.1016/s0163-4453(97)93232-1
47. Casciani F, Trudeau MT, Vollmer CM Jr. Perioperative Immunization for Splenectomy and the Surgeon's Responsibility: A Review. JAMA Surg. 2020;155(11):1068-77. DOI:10.1001/jamasurg.2020.1463
48. Демин А.А., Кобалава Ж.Д., Скопин И.И., и др. Инфекционный эндокардит и инфекция внутрисердечных устройств. Клинические рекомендации 2021. Российский кардиологический журнал. 2022;27(10):5233 [Demin AA, Kobalava ZD, Skopin II, et al. Infectious endocarditis and infection of intracardiac devices in adults. Clinical guidelines 2021. Russian Journal of Cardiology. 2022;27(10):5233 (in Russian)]. DOI:10.15829/1560-4071-2022-5233
49. Чучалин А.Г., Брико Н.И., Авдеев С.Н., и др. Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции у взрослых. Пульмонология. 2019;29(1):19-34 [Chuchalin AG, Briko NI, Avdeev SN, et al. Federal Clinical Guidelines on Preventive Vaccination Against Pneumococcal infections in Adults. Russian Pulmonology. 2019;29(1):19-34 (in Russian)]. DOI:10.18093/0869-0189-2019-29-1-19-34
50. Ren S, Hansbro PM, Srikusalanukul W, et al. Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial. Atherosclerosis. 2022;346:68-74. DOI:10.1016/j.atherosclerosis.2022.02.011
2. Avdeev SN, Dekhnich AV, Zaitsev AA, et al. Vnebol'nichnaia pnevmoniia u vzroslykh. Klinicheskie rekomendatsii. 2024. Available at: https://spulmo.ru/upload/KR-vnebolnichnaya-pnevmoniya-u-vzroslyh-2024.pdf. Accessed: 18.04.2025 (in Russian).
3. Podzolkov VI, Dragomiretskaya NA, Medvedev ID, et al. Levels of cardiac biomarkers and three-year survival rate in hospitalized patients with heart failure and community-acquired pneumonia. Russian Journal of Cardiology. 2024;29(6):5875 (in Russian). DOI:10.15829/1560-4071-2024-5875
4. Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation. 2012;125(6):773-81. DOI:10.1161/CIRCULATIONAHA.111.040766
5. Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med. 2008;168(8):847-54. DOI:10.1001/archinte.168.8.847
6. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007;45(2):158-65. DOI:10.1086/518849
7. Chen LF, Chen HP, Huang YS, et al. Pneumococcal pneumonia and the risk of stroke: a population-based follow-up study. PLoS One. 2012;7(12):e51452. DOI:10.1371/journal.pone.0051452
8. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-25. DOI:10.1056/NEJMoa1408544
9. Arutyunov AG, Dragunov DO, Arutyunov GP, et al. First Open Study of Syndrome of Acute Decompensation of Heart Failure and Concomitant Diseases in Russian Federation: Independent Registry ORAKUL. Kardiologiia. 2015;55(5):12-21 (in Russian). DOI:10.18565/cardio.2015.5.12-21
10. Briko NI, Korshunov VA, Lomonosov KS. Pneumococcal infection in Russia: state of the issue. Annals of the Russian Academy of Medical Sciences. 2021;76(1):28-42 (in Russian). DOI:10.15690/vramn1404
11. Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia (Nathan). 2020;12:11. DOI:10.1186/s41479-020-00074-3
12. Zakharenkov IA, Rachina SA, Dekhnich NN, et al. Etiology of severe community-acquired pneumonia in adults: results of the first Russian multicenter study. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(1):36-42 (in Russian). DOI:10.26442/ 00403660.2020.01.000491
13. Brown AO, Mann B, Gao G, et al. Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog. 2014;10(9):e1004383. DOI:10.1371/journal.ppat.1004383
14. Gilley RP, González-Juarbe N, Shenoy AT, et al. Infiltrated Macrophages Die of Pneumolysin-Mediated Necroptosis following Pneumococcal Myocardial Invasion. Infect Immun. 2016;84(5):1457-69. DOI:10.1128/IAI.00007-16
15. Alhamdi Y, Neill DR, Abrams ST, et al. Circulating Pneumolysin Is a Potent Inducer of Cardiac Injury during Pneumococcal Infection. PLoS Pathog. 2015;11(5):e1004836. DOI:10.1371/journal.ppat.1004836
16. Reyes LF, Restrepo MI, Hinojosa CA, et al. Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling. Am J Respir Crit Care Med. 2017;196(5):609-20. DOI:10.1164/rccm.201701-0104OC
17. Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med. 2011;8(6):e1001048. DOI:10.1371/journal.pmed.1001048
18. Bazaz R, Francis S, Dockrell D. 215 Increased Atherosclerotic Plaque Macrophage Content following Streptococcus Pneumoniae Pneumonia. Heart. 2015;101(Suppl. 4):A117.2-A118. DOI:10.1136/heartjnl-2015-308066.215
19. Restrepo MI, Reyes LF, Anzueto A. Complication of Community-Acquired Pneumonia (Including Cardiac Complications). Semin Respir Crit Care Med. 2016;37(6):897-904. DOI:10.1055/s-0036-1593754
20. Nel JG, Durandt C, Mitchell TJ, et al. Pneumolysin Mediates Platelet Activation In Vitro. Lung. 2016;194(4):589-93. DOI:10.1007/s00408-016-9900-5
21. Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264-74. DOI:10.1001/jama.2014.18229
22. Mamcarz A, Wełnicki M, Drożdż J, et al. The role of pneumococcal vaccination in reducing cardiovascular risk in cardiac patients: Expert opinion of the Prevention Committee of the Polish Cardiac Society supported by the Polish Vaccinology Society. Kardiol Pol. 2023;81(10):1038-106. DOI:10.33963/v.kp.96718
23. Falkenhorst G, Remschmidt C, Harder T, et al. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis. PLoS One. 2017;12(1):e0169368. DOI:10.1371/journal.pone.0169368
24. Diao WQ, Shen N, Yu PX, et al. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials. Vaccine. 2016;34(13):1496-503. DOI:10.1016/j.vaccine.2016.02.023
25. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010;10(2):83-92. DOI:10.1016/S1473-3099(09)70331-7
26. Ciszewski A. Cardioprotective effect of influenza and pneumococcal vaccination in patients with cardiovascular diseases. Vaccine. 2018;36(2):202-10. DOI:10.1016/j.vaccine.2017.11.078
27. Hörkkö S, Bird DA, Miller E, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest. 1999;103(1):117-28. DOI:10.1172/JCI4533
28. Shaw PX, Hörkkö S, Chang MK, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest. 2000;105(12):1731-40. DOI:10.1172/JCI8472
29. Ren S, Hure A, Peel R, et al. Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE). Am Heart J. 2016;177:58-65. DOI:10.1016/j.ahj.2016.04.003
30. Drapkina OM, Briko NI, Kostinov MP, et al. Immunizatsiia vzroslykh. Metodicheskie rekomendatsii. Moscow: FGBU «NMITs TPM» Minzdrava Rossii, 2020 (in Russian).
31. Korshunov VA, Briko NI, Polibin RV, et al. Pneumococcal Vaccination Coverage Among Adults at Risk in the Russian Federation. Epidemiology and Vaccinal Prevention. 2025;23(6):13-23 (in Russian). DOI:10.31631/2073-3046-2024-23-6-13-23
32. Marra F, Zhang A, Gillman E, et al. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis. Int J Infect Dis. 2020;99:204-13. DOI:10.1016/j.ijid.2020.07.038
33. Jaiswal V, Ang SP, Lnu K, et al. Effect of Pneumococcal Vaccine on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. J Clin Med. 2022;11(13):3799. DOI:10.3390/jcm11133799
34. Bhatt AS, Liang L, DeVore AD, et al. Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart Failure. JACC Heart Fail. 2018;6(10):844-55. DOI:10.1016/j.jchf.2018.04.012
35. Papagiannis D, Kourek C, Briasoulis A, et al. Pneumococcal and Influenza Vaccination Coverage in Patients with Heart Failure: A Systematic Review. J Clin Med. 2024;13(11):3029. DOI:10.3390/jcm13113029
36. Rudakova AV, Brico NI, Lobzin YV, et al. Cost-effectiveness of pneumococcal vaccination among patients with chronic heart failure. Kardiologiia. 2023;63(5):19-26 (in Russian). DOI:10.18087/cardio.2023.5.n2378
37. Ignatova GL, Antonov VN. Analysis of the influence of vaccination against pneumococcal infection on the course of comorbid pathology in patients with chronic obstructive pulmonary disease and chronic heart failure. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(8):53-62 (in Russian).
38. Vlachopoulos CV, Terentes-Printzios DG, Aznaouridis KA, et al. Association between pneumococcal vaccination and cardiovascular outcomes: a systematic review and meta-analysis of cohort studies. Eur J Prev Cardiol. 2015;22(9):1185-99. DOI:10.1177/2047487314549512
39. Antunes M, Duarte GS, Brito D, et al. Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. 2021;7(1):97-106. DOI:10.1093/ehjqcco/qcaa030
40. Avdeev SN, Barbarash OL, Valieva ZS, et al. 2024 Clinical practice guidelines for pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian Journal of Cardiology. 2024;29(11):6161 (in Russian). DOI:10.15829/1560-4071-2024-6161
41. Galyavich AS, Tereshchenko SN, Uskach TM, et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):6162 (in Russian). DOI:10.15829/1560-4071-2024-6162
42. Arutyunov GP, Paleev FN, Moiseeva OM, et al. 2020 Clinical practice guidelines for Myocarditis in adults. Russian Journal of Cardiology. 2021;26(11):4790 (in Russian). DOI:10.15829/1560-4071-2021-4790
43. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216-23. DOI:10.7326/0003-4819-107-2-216
44. Chazova IE, Martynyuk TV, Valieva ZS, et al. Eurasian association of cardiology (eac) guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (2020). Eurasian Heart Journal. 2021;(1):6-43 (in Russian). DOI:10.38109/2225-1685-2021-1-6-43
45. Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J. 2023;44(39):3948-4042. DOI:10.1093/eurheartj/ehad193
46. Waghorn DJ, Mayon-White RT. A study of 42 episodes of overwhelming post-splenectomy infection: is current guidance for asplenic individuals being followed? J Infect. 1997;35(3):289-94. DOI:10.1016/s0163-4453(97)93232-1
47. Casciani F, Trudeau MT, Vollmer CM Jr. Perioperative Immunization for Splenectomy and the Surgeon's Responsibility: A Review. JAMA Surg. 2020;155(11):1068-77. DOI:10.1001/jamasurg.2020.1463
48. Demin AA, Kobalava ZD, Skopin II, et al. Infectious endocarditis and infection of intracardiac devices in adults. Clinical guidelines 2021. Russian Journal of Cardiology. 2022;27(10):5233 (in Russian). DOI:10.15829/1560-4071-2022-5233
49. Chuchalin AG, Briko NI, Avdeev SN, et al. Federal Clinical Guidelines on Preventive Vaccination Against Pneumococcal infections in Adults. Russian Pulmonology. 2019;29(1):19-34 (in Russian). DOI:10.18093/0869-0189-2019-29-1-19-34
50. Ren S, Hansbro PM, Srikusalanukul W, et al. Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial. Atherosclerosis. 2022;346:68-74. DOI:10.1016/j.atherosclerosis.2022.02.011
2. Авдеев С.Н., Дехнич А.В., Зайцев А.А., и др. Внебольничная пневмония у взрослых. Клинические рекомендации. 2024. Режим доступа: https://spulmo.ru/upload/KR-vnebolnichnaya-pnevmoniya-u-vzros lyh-2024.pdf. Ссылка активна на 18.04.2025 [Avdeev SN, Dekhnich AV, Zaitsev AA, et al. Vnebol'nichnaia pnevmoniia u vzroslykh. Klinicheskie rekomendatsii. 2024. Available at: https://spulmo.ru/upload/KR-vnebolnichnaya-pnevmoniya-u-vzroslyh-2024.pdf. Accessed: 18.04.2025 (in Russian)].
3. Подзолков В.И., Драгомирецкая Н.А., Медведев И.Д., и др. Уровни кардиоспецифичных биомаркеров и показатели трехлетней выживаемости у госпитализированных больных с хронической сердечной недостаточностью и внебольничной пневмонией. Российский кардиологический журнал. 2024;29(6):5875 [Podzolkov VI, Dragomiretskaya NA, Medvedev ID, et al. Levels of cardiac biomarkers and three-year survival rate in hospitalized patients with heart failure and community-acquired pneumonia. Russian Journal of Cardiology. 2024;29(6):5875 (in Russian)]. DOI:10.15829/1560-4071-2024-5875
4. Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation. 2012;125(6):773-81. DOI:10.1161/CIRCULATIONAHA.111.040766
5. Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med. 2008;168(8):847-54. DOI:10.1001/archinte.168.8.847
6. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007;45(2):158-65. DOI:10.1086/518849
7. Chen LF, Chen HP, Huang YS, et al. Pneumococcal pneumonia and the risk of stroke: a population-based follow-up study. PLoS One. 2012;7(12):e51452. DOI:10.1371/journal.pone.0051452
8. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-25. DOI:10.1056/NEJMoa1408544
9. Арутюнов А.Г., Драгунов Д.О., Арутюнов Г.П., и др. Первое открытое исследование синдрома острой декомпенсации сердечной недостаточности и сопутствующих заболеваний в Российской Федерации. Независимый регистр ОРАКУЛ-РФ. Кардиология. 2015;55(5):12-21 [Arutyunov AG, Dragunov DO, Arutyunov GP, et al. First Open Study of Syndrome of Acute Decompensation of Heart Failure and Concomitant Diseases in Russian Federation: Independent Registry ORAKUL. Kardiologiia. 2015;55(5):12-21 (in Russian)]. DOI:10.18565/cardio.2015.5.12-21
10. Брико Н.И., Коршунов В.А., Ломоносов К.С. Пневмококковая инфекция в Российской Федерации: состояние проблемы. Вестник Российской академии медицинских наук. 2021;76(1):28-42 [Briko NI, Korshunov VA, Lomonosov KS. Pneumococcal infection in Russia: state of the issue. Annals of the Russian Academy of Medical Sciences. 2021;76(1):28-42 (in Russian)]. DOI:10.15690/vramn1404
11. Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia (Nathan). 2020;12:11. DOI:10.1186/s41479-020-00074-3
12. Захаренков И.А., Рачина С.А., Дехнич Н.Н., и др. Этиология тяжелой внебольничной пневмонии у взрослых: результаты первого российского многоцентрового исследования. Терапевтический архив. 2020;92(1):36-42 [Zakharenkov IA, Rachina SA, Dekhnich NN, et al. Etiology of severe community-acquired pneumonia in adults: results of the first Russian multicenter study. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(1):36-42 (in Russian)]. DOI:10.26442/ 00403660.2020.01.000491
13. Brown AO, Mann B, Gao G, et al. Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog. 2014;10(9):e1004383. DOI:10.1371/journal.ppat.1004383
14. Gilley RP, González-Juarbe N, Shenoy AT, et al. Infiltrated Macrophages Die of Pneumolysin-Mediated Necroptosis following Pneumococcal Myocardial Invasion. Infect Immun. 2016;84(5):1457-69. DOI:10.1128/IAI.00007-16
15. Alhamdi Y, Neill DR, Abrams ST, et al. Circulating Pneumolysin Is a Potent Inducer of Cardiac Injury during Pneumococcal Infection. PLoS Pathog. 2015;11(5):e1004836. DOI:10.1371/journal.ppat.1004836
16. Reyes LF, Restrepo MI, Hinojosa CA, et al. Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling. Am J Respir Crit Care Med. 2017;196(5):609-20. DOI:10.1164/rccm.201701-0104OC
17. Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med. 2011;8(6):e1001048. DOI:10.1371/journal.pmed.1001048
18. Bazaz R, Francis S, Dockrell D. 215 Increased Atherosclerotic Plaque Macrophage Content following Streptococcus Pneumoniae Pneumonia. Heart. 2015;101(Suppl. 4):A117.2-A118. DOI:10.1136/heartjnl-2015-308066.215
19. Restrepo MI, Reyes LF, Anzueto A. Complication of Community-Acquired Pneumonia (Including Cardiac Complications). Semin Respir Crit Care Med. 2016;37(6):897-904. DOI:10.1055/s-0036-1593754
20. Nel JG, Durandt C, Mitchell TJ, et al. Pneumolysin Mediates Platelet Activation In Vitro. Lung. 2016;194(4):589-93. DOI:10.1007/s00408-016-9900-5
21. Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264-74. DOI:10.1001/jama.2014.18229
22. Mamcarz A, Wełnicki M, Drożdż J, et al. The role of pneumococcal vaccination in reducing cardiovascular risk in cardiac patients: Expert opinion of the Prevention Committee of the Polish Cardiac Society supported by the Polish Vaccinology Society. Kardiol Pol. 2023;81(10):1038-106. DOI:10.33963/v.kp.96718
23. Falkenhorst G, Remschmidt C, Harder T, et al. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis. PLoS One. 2017;12(1):e0169368. DOI:10.1371/journal.pone.0169368
24. Diao WQ, Shen N, Yu PX, et al. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials. Vaccine. 2016;34(13):1496-503. DOI:10.1016/j.vaccine.2016.02.023
25. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010;10(2):83-92. DOI:10.1016/S1473-3099(09)70331-7
26. Ciszewski A. Cardioprotective effect of influenza and pneumococcal vaccination in patients with cardiovascular diseases. Vaccine. 2018;36(2):202-10. DOI:10.1016/j.vaccine.2017.11.078
27. Hörkkö S, Bird DA, Miller E, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest. 1999;103(1):117-28. DOI:10.1172/JCI4533
28. Shaw PX, Hörkkö S, Chang MK, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest. 2000;105(12):1731-40. DOI:10.1172/JCI8472
29. Ren S, Hure A, Peel R, et al. Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE). Am Heart J. 2016;177:58-65. DOI:10.1016/j.ahj.2016.04.003
30. Драпкина О.М., Брико Н.И., Костинов М.П., и др. Иммунизация взрослых. Методические рекомендации. М.: ФГБУ «НМИЦ ТПМ» Минздрава России, 2020 [Drapkina OM, Briko NI, Kostinov MP, et al. Immunizatsiia vzroslykh. Metodicheskie rekomendatsii. Moscow: FGBU «NMITs TPM» Minzdrava Rossii, 2020 (in Russian)].
31. Коршунов В.А., Брико Н.И., Полибин Р.В., и др. Охват вакцинацией против пневмококковой инфекции взрослых групп риска в Российской Федерации. Эпидемиология и Вакцинопрофилактика. 2025;23(6):13-23 [Korshunov VA, Briko NI, Polibin RV, et al. Pneumococcal Vaccination Coverage Among Adults at Risk in the Russian Federation. Epidemiology and Vaccinal Prevention. 2025;23(6):13-23 (in Russian)]. DOI:10.31631/2073-3046-2024-23-6-13-23
32. Marra F, Zhang A, Gillman E, et al. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis. Int J Infect Dis. 2020;99:204-13. DOI:10.1016/j.ijid.2020.07.038
33. Jaiswal V, Ang SP, Lnu K, et al. Effect of Pneumococcal Vaccine on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. J Clin Med. 2022;11(13):3799. DOI:10.3390/jcm11133799
34. Bhatt AS, Liang L, DeVore AD, et al. Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart Failure. JACC Heart Fail. 2018;6(10):844-55. DOI:10.1016/j.jchf.2018.04.012
35. Papagiannis D, Kourek C, Briasoulis A, et al. Pneumococcal and Influenza Vaccination Coverage in Patients with Heart Failure: A Systematic Review. J Clin Med. 2024;13(11):3029. DOI:10.3390/jcm13113029
36. Рудакова А.В., Брико Н.И., Лобзин Ю.В., и др. Фармакоэкономическая эффективность вакцинации против пневмококковой инфекции пациентов с хронической сердечной недостаточностью. Кардиология. 2023;63(5):19-26 [Rudakova AV, Brico NI, Lobzin YV, et al. Cost-effectiveness of pneumococcal vaccination among patients with chronic heart failure. Kardiologiia. 2023;63(5):19-26 (in Russian)]. DOI:10.18087/cardio.2023.5.n2378
37. Игнатова Г.Л., Антонов В.Н. Анализ влияния вакцинации против пневмококковой инфекции на течение коморбидной патологии у пациентов с хронической обструктивной болезнью легких и хронической сердечной недостаточностью. Терапевтический архив. 2018;90(8):53-62 [Ignatova GL, Antonov VN. Analysis of the influence of vaccination against pneumococcal infection on the course of comorbid pathology in patients with chronic obstructive pulmonary disease and chronic heart failure. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(8):53-62 (in Russian)].
38. Vlachopoulos CV, Terentes-Printzios DG, Aznaouridis KA, et al. Association between pneumococcal vaccination and cardiovascular outcomes: a systematic review and meta-analysis of cohort studies. Eur J Prev Cardiol. 2015;22(9):1185-99. DOI:10.1177/2047487314549512
39. Antunes M, Duarte GS, Brito D, et al. Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. 2021;7(1):97-106. DOI:10.1093/ehjqcco/qcaa030
40. Авдеев С.Н., Барбараш О.Л., Валиева З.С., и др. Легочная гипертензия, в том числе хроническая тромбоэмболическая легочная гипертензия. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(11):6161 [Avdeev SN, Barbarash OL, Valieva ZS, et al. 2024 Clinical practice guidelines for pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian Journal of Cardiology. 2024;29(11):6161 (in Russian)]. DOI:10.15829/1560-4071-2024-6161
41. Галявич А.С., Терещенко С.Н., Ускач Т.М., и др. Хроническая сердечная недостаточность. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(11):6162 [Galyavich AS, Tereshchenko SN, Uskach TM, et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):6162 (in Russian)]. DOI:10.15829/1560-4071-2024-6162
42. Арутюнов Г.П., Палеев Ф.Н., Моисеева О.М., и др. Миокардиты у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(11):4790 [Arutyunov GP, Paleev FN, Moiseeva OM, et al. 2020 Clinical practice guidelines for Myocarditis in adults. Russian Journal of Cardiology. 2021;26(11):4790 (in Russian)]. DOI:10.15829/1560-4071-2021-4790
43. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216-23. DOI:10.7326/0003-4819-107-2-216
44. Чазова И.Е., Мартынюк Т.В., Валиева З.С., и др. Евразийские рекомендации по диагностике и лечению хронической тромбоэмболической легочной гипертензии (2020). Евразийский Кардиологический Журнал. 2021;(1):6-43 [Chazova IE, Martynyuk TV, Valieva ZS, et al. Eurasian association of cardiology (eac) guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (2020). Eurasian Heart Journal. 2021;(1):6-43 (in Russian)]. DOI:10.38109/2225-1685-2021-1-6-43
45. Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J. 2023;44(39):3948-4042. DOI:10.1093/eurheartj/ehad193
46. Waghorn DJ, Mayon-White RT. A study of 42 episodes of overwhelming post-splenectomy infection: is current guidance for asplenic individuals being followed? J Infect. 1997;35(3):289-94. DOI:10.1016/s0163-4453(97)93232-1
47. Casciani F, Trudeau MT, Vollmer CM Jr. Perioperative Immunization for Splenectomy and the Surgeon's Responsibility: A Review. JAMA Surg. 2020;155(11):1068-77. DOI:10.1001/jamasurg.2020.1463
48. Демин А.А., Кобалава Ж.Д., Скопин И.И., и др. Инфекционный эндокардит и инфекция внутрисердечных устройств. Клинические рекомендации 2021. Российский кардиологический журнал. 2022;27(10):5233 [Demin AA, Kobalava ZD, Skopin II, et al. Infectious endocarditis and infection of intracardiac devices in adults. Clinical guidelines 2021. Russian Journal of Cardiology. 2022;27(10):5233 (in Russian)]. DOI:10.15829/1560-4071-2022-5233
49. Чучалин А.Г., Брико Н.И., Авдеев С.Н., и др. Федеральные клинические рекомендации по вакцинопрофилактике пневмококковой инфекции у взрослых. Пульмонология. 2019;29(1):19-34 [Chuchalin AG, Briko NI, Avdeev SN, et al. Federal Clinical Guidelines on Preventive Vaccination Against Pneumococcal infections in Adults. Russian Pulmonology. 2019;29(1):19-34 (in Russian)]. DOI:10.18093/0869-0189-2019-29-1-19-34
50. Ren S, Hansbro PM, Srikusalanukul W, et al. Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial. Atherosclerosis. 2022;346:68-74. DOI:10.1016/j.atherosclerosis.2022.02.011
________________________________________________
2. Avdeev SN, Dekhnich AV, Zaitsev AA, et al. Vnebol'nichnaia pnevmoniia u vzroslykh. Klinicheskie rekomendatsii. 2024. Available at: https://spulmo.ru/upload/KR-vnebolnichnaya-pnevmoniya-u-vzroslyh-2024.pdf. Accessed: 18.04.2025 (in Russian).
3. Podzolkov VI, Dragomiretskaya NA, Medvedev ID, et al. Levels of cardiac biomarkers and three-year survival rate in hospitalized patients with heart failure and community-acquired pneumonia. Russian Journal of Cardiology. 2024;29(6):5875 (in Russian). DOI:10.15829/1560-4071-2024-5875
4. Corrales-Medina VF, Musher DM, Wells GA, et al. Cardiac complications in patients with community-acquired pneumonia: incidence, timing, risk factors, and association with short-term mortality. Circulation. 2012;125(6):773-81. DOI:10.1161/CIRCULATIONAHA.111.040766
5. Fonarow GC, Abraham WT, Albert NM, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: findings from OPTIMIZE-HF. Arch Intern Med. 2008;168(8):847-54. DOI:10.1001/archinte.168.8.847
6. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007;45(2):158-65. DOI:10.1086/518849
7. Chen LF, Chen HP, Huang YS, et al. Pneumococcal pneumonia and the risk of stroke: a population-based follow-up study. PLoS One. 2012;7(12):e51452. DOI:10.1371/journal.pone.0051452
8. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372(12):1114-25. DOI:10.1056/NEJMoa1408544
9. Arutyunov AG, Dragunov DO, Arutyunov GP, et al. First Open Study of Syndrome of Acute Decompensation of Heart Failure and Concomitant Diseases in Russian Federation: Independent Registry ORAKUL. Kardiologiia. 2015;55(5):12-21 (in Russian). DOI:10.18565/cardio.2015.5.12-21
10. Briko NI, Korshunov VA, Lomonosov KS. Pneumococcal infection in Russia: state of the issue. Annals of the Russian Academy of Medical Sciences. 2021;76(1):28-42 (in Russian). DOI:10.15690/vramn1404
11. Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia (Nathan). 2020;12:11. DOI:10.1186/s41479-020-00074-3
12. Zakharenkov IA, Rachina SA, Dekhnich NN, et al. Etiology of severe community-acquired pneumonia in adults: results of the first Russian multicenter study. Terapevticheskii Arkhiv (Ter. Arkh.). 2020;92(1):36-42 (in Russian). DOI:10.26442/ 00403660.2020.01.000491
13. Brown AO, Mann B, Gao G, et al. Streptococcus pneumoniae translocates into the myocardium and forms unique microlesions that disrupt cardiac function. PLoS Pathog. 2014;10(9):e1004383. DOI:10.1371/journal.ppat.1004383
14. Gilley RP, González-Juarbe N, Shenoy AT, et al. Infiltrated Macrophages Die of Pneumolysin-Mediated Necroptosis following Pneumococcal Myocardial Invasion. Infect Immun. 2016;84(5):1457-69. DOI:10.1128/IAI.00007-16
15. Alhamdi Y, Neill DR, Abrams ST, et al. Circulating Pneumolysin Is a Potent Inducer of Cardiac Injury during Pneumococcal Infection. PLoS Pathog. 2015;11(5):e1004836. DOI:10.1371/journal.ppat.1004836
16. Reyes LF, Restrepo MI, Hinojosa CA, et al. Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling. Am J Respir Crit Care Med. 2017;196(5):609-20. DOI:10.1164/rccm.201701-0104OC
17. Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med. 2011;8(6):e1001048. DOI:10.1371/journal.pmed.1001048
18. Bazaz R, Francis S, Dockrell D. 215 Increased Atherosclerotic Plaque Macrophage Content following Streptococcus Pneumoniae Pneumonia. Heart. 2015;101(Suppl. 4):A117.2-A118. DOI:10.1136/heartjnl-2015-308066.215
19. Restrepo MI, Reyes LF, Anzueto A. Complication of Community-Acquired Pneumonia (Including Cardiac Complications). Semin Respir Crit Care Med. 2016;37(6):897-904. DOI:10.1055/s-0036-1593754
20. Nel JG, Durandt C, Mitchell TJ, et al. Pneumolysin Mediates Platelet Activation In Vitro. Lung. 2016;194(4):589-93. DOI:10.1007/s00408-016-9900-5
21. Corrales-Medina VF, Alvarez KN, Weissfeld LA, et al. Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;313(3):264-74. DOI:10.1001/jama.2014.18229
22. Mamcarz A, Wełnicki M, Drożdż J, et al. The role of pneumococcal vaccination in reducing cardiovascular risk in cardiac patients: Expert opinion of the Prevention Committee of the Polish Cardiac Society supported by the Polish Vaccinology Society. Kardiol Pol. 2023;81(10):1038-106. DOI:10.33963/v.kp.96718
23. Falkenhorst G, Remschmidt C, Harder T, et al. Effectiveness of the 23-Valent Pneumococcal Polysaccharide Vaccine (PPV23) against Pneumococcal Disease in the Elderly: Systematic Review and Meta-Analysis. PLoS One. 2017;12(1):e0169368. DOI:10.1371/journal.pone.0169368
24. Diao WQ, Shen N, Yu PX, et al. Efficacy of 23-valent pneumococcal polysaccharide vaccine in preventing community-acquired pneumonia among immunocompetent adults: A systematic review and meta-analysis of randomized trials. Vaccine. 2016;34(13):1496-503. DOI:10.1016/j.vaccine.2016.02.023
25. Corrales-Medina VF, Madjid M, Musher DM. Role of acute infection in triggering acute coronary syndromes. Lancet Infect Dis. 2010;10(2):83-92. DOI:10.1016/S1473-3099(09)70331-7
26. Ciszewski A. Cardioprotective effect of influenza and pneumococcal vaccination in patients with cardiovascular diseases. Vaccine. 2018;36(2):202-10. DOI:10.1016/j.vaccine.2017.11.078
27. Hörkkö S, Bird DA, Miller E, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest. 1999;103(1):117-28. DOI:10.1172/JCI4533
28. Shaw PX, Hörkkö S, Chang MK, et al. Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity. J Clin Invest. 2000;105(12):1731-40. DOI:10.1172/JCI8472
29. Ren S, Hure A, Peel R, et al. Rationale and design of a randomized controlled trial of pneumococcal polysaccharide vaccine for prevention of cardiovascular events: The Australian Study for the Prevention through Immunization of Cardiovascular Events (AUSPICE). Am Heart J. 2016;177:58-65. DOI:10.1016/j.ahj.2016.04.003
30. Drapkina OM, Briko NI, Kostinov MP, et al. Immunizatsiia vzroslykh. Metodicheskie rekomendatsii. Moscow: FGBU «NMITs TPM» Minzdrava Rossii, 2020 (in Russian).
31. Korshunov VA, Briko NI, Polibin RV, et al. Pneumococcal Vaccination Coverage Among Adults at Risk in the Russian Federation. Epidemiology and Vaccinal Prevention. 2025;23(6):13-23 (in Russian). DOI:10.31631/2073-3046-2024-23-6-13-23
32. Marra F, Zhang A, Gillman E, et al. The protective effect of pneumococcal vaccination on cardiovascular disease in adults: A systematic review and meta-analysis. Int J Infect Dis. 2020;99:204-13. DOI:10.1016/j.ijid.2020.07.038
33. Jaiswal V, Ang SP, Lnu K, et al. Effect of Pneumococcal Vaccine on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis. J Clin Med. 2022;11(13):3799. DOI:10.3390/jcm11133799
34. Bhatt AS, Liang L, DeVore AD, et al. Vaccination Trends in Patients With Heart Failure: Insights From Get With The Guidelines-Heart Failure. JACC Heart Fail. 2018;6(10):844-55. DOI:10.1016/j.jchf.2018.04.012
35. Papagiannis D, Kourek C, Briasoulis A, et al. Pneumococcal and Influenza Vaccination Coverage in Patients with Heart Failure: A Systematic Review. J Clin Med. 2024;13(11):3029. DOI:10.3390/jcm13113029
36. Rudakova AV, Brico NI, Lobzin YV, et al. Cost-effectiveness of pneumococcal vaccination among patients with chronic heart failure. Kardiologiia. 2023;63(5):19-26 (in Russian). DOI:10.18087/cardio.2023.5.n2378
37. Ignatova GL, Antonov VN. Analysis of the influence of vaccination against pneumococcal infection on the course of comorbid pathology in patients with chronic obstructive pulmonary disease and chronic heart failure. Terapevticheskii Arkhiv (Ter. Arkh.). 2018;90(8):53-62 (in Russian).
38. Vlachopoulos CV, Terentes-Printzios DG, Aznaouridis KA, et al. Association between pneumococcal vaccination and cardiovascular outcomes: a systematic review and meta-analysis of cohort studies. Eur J Prev Cardiol. 2015;22(9):1185-99. DOI:10.1177/2047487314549512
39. Antunes M, Duarte GS, Brito D, et al. Pneumococcal vaccination in adults at very high risk or with established cardiovascular disease: systematic review and meta-analysis. Eur Heart J Qual Care Clin Outcomes. 2021;7(1):97-106. DOI:10.1093/ehjqcco/qcaa030
40. Avdeev SN, Barbarash OL, Valieva ZS, et al. 2024 Clinical practice guidelines for pulmonary hypertension, including chronic thromboembolic pulmonary hypertension. Russian Journal of Cardiology. 2024;29(11):6161 (in Russian). DOI:10.15829/1560-4071-2024-6161
41. Galyavich AS, Tereshchenko SN, Uskach TM, et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024;29(11):6162 (in Russian). DOI:10.15829/1560-4071-2024-6162
42. Arutyunov GP, Paleev FN, Moiseeva OM, et al. 2020 Clinical practice guidelines for Myocarditis in adults. Russian Journal of Cardiology. 2021;26(11):4790 (in Russian). DOI:10.15829/1560-4071-2021-4790
43. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. 1987;107(2):216-23. DOI:10.7326/0003-4819-107-2-216
44. Chazova IE, Martynyuk TV, Valieva ZS, et al. Eurasian association of cardiology (eac) guidelines for the diagnosis and treatment of chronic thromboembolic pulmonary hypertension (2020). Eurasian Heart Journal. 2021;(1):6-43 (in Russian). DOI:10.38109/2225-1685-2021-1-6-43
45. Delgado V, Ajmone Marsan N, de Waha S, et al. 2023 ESC Guidelines for the management of endocarditis. Eur Heart J. 2023;44(39):3948-4042. DOI:10.1093/eurheartj/ehad193
46. Waghorn DJ, Mayon-White RT. A study of 42 episodes of overwhelming post-splenectomy infection: is current guidance for asplenic individuals being followed? J Infect. 1997;35(3):289-94. DOI:10.1016/s0163-4453(97)93232-1
47. Casciani F, Trudeau MT, Vollmer CM Jr. Perioperative Immunization for Splenectomy and the Surgeon's Responsibility: A Review. JAMA Surg. 2020;155(11):1068-77. DOI:10.1001/jamasurg.2020.1463
48. Demin AA, Kobalava ZD, Skopin II, et al. Infectious endocarditis and infection of intracardiac devices in adults. Clinical guidelines 2021. Russian Journal of Cardiology. 2022;27(10):5233 (in Russian). DOI:10.15829/1560-4071-2022-5233
49. Chuchalin AG, Briko NI, Avdeev SN, et al. Federal Clinical Guidelines on Preventive Vaccination Against Pneumococcal infections in Adults. Russian Pulmonology. 2019;29(1):19-34 (in Russian). DOI:10.18093/0869-0189-2019-29-1-19-34
50. Ren S, Hansbro PM, Srikusalanukul W, et al. Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial. Atherosclerosis. 2022;346:68-74. DOI:10.1016/j.atherosclerosis.2022.02.011
Авторы
Г.В. Щелкова, С.Ю. Яровой, Е.О. Диневич*, И.Е. Чазова
ФГБУ «Национальный медицинский исследовательский центр кардиологии им. акад. Е.И. Чазова» Минздрава России, Москва, Россия
*katya.seliverstova@gmail.com
Chazov National Medical Research Center of Cardiology, Moscow, Russia
*katya.seliverstova@gmail.com
ФГБУ «Национальный медицинский исследовательский центр кардиологии им. акад. Е.И. Чазова» Минздрава России, Москва, Россия
*katya.seliverstova@gmail.com
________________________________________________
Chazov National Medical Research Center of Cardiology, Moscow, Russia
*katya.seliverstova@gmail.com
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.